Keurig Dr Pepper Inc. Common Stock vs Mesoblast Limited — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $31.72 (market cap $42.54B), while Mesoblast Limited trades at $14.3 (market cap $1.75B). The key difference: Keurig Dr Pepper Inc. Common Stock is far larger — about 24.3× Mesoblast Limited's market cap, and Keurig Dr Pepper Inc. Common Stock pays a 2.94% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 1 Days and Mesoblast Limited for 15 Days on average.
| KDP | MESO | |
|---|---|---|
Market Cap | $42.54B | $1.75B |
Volume | 14,530,234 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $33.50 | $20.96 |
52-Week Low | $25.31 | $13.19 |
Typical Hold Time | 1 Days | 15 Days |
Enterprise Value | $71.00B | $1.83B |
Dividend Yield | 2.94% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →